The 221b Foundation and LogicInk Announce License Agreement to Utilize Sherlock Biosciences’ CRISPR Technology to Develop Instrument-free Diagnostic for COVID-19
The 221b Foundation and LogicInk Announce License Agreement to Utilize Sherlock Biosciences’ CRISPR Technology to Develop Instrument-free Diagnostic for COVID-19
$content}
Source: FintechNews
Tags: Business